

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10580962
Filing Date	2006-05-31
First Named Inventor	Erik Buntinx
Art Unit	1617
Examiner Name	PIHONAK, Sarah
Attorney Docket Number	29248-29

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5554383		1996-09-10	Dodman	
	2	5762960		1998-06-09	Dodman	
	3	5759837		1998-06-02	Kuhajda et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20030032636	A1	2003-02-13	Cremers et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
Eng. abs.	1	4039631	DE	A1	1992-06-17	Dr. Kerstin Bode-Greuel	Abstract	<input checked="" type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number		10580962
	Filing Date		2006-05-31
	First Named Inventor		Erik Buntinx
	Art Unit		1617
	Examiner Name		PIHONAK, Sarah
	Attorney Docket Number		29248-29

	2	2461248	CA		2009-09-08	Pharmaneuroboost N.V.	Notice of Allowance	<input type="checkbox"/>
--	---	---------	----	--	------------	-----------------------	---------------------	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	USPTO Office Action dated 06/10/2009 in connection with related Application Serial No. 10/725,965 filed 12/02/2003, Examiner Umamaheswari Ramachandran, Art Unit 1617.	<input type="checkbox"/>
	2	USPTO Office Action dated 08/05/2009 in connection with related Application Serial No. 10/752,423 filed 01/06/2004, Examiner Umamaheswari Ramachandran, Art Unit 1617.	<input type="checkbox"/>
	3	USPTO Office Action dated 11/10/2009 in connection with related Application Serial No. 10/803,793 filed 03/18/2004, Examiner Benjamin J. Packard, Art Unit 1612.	<input type="checkbox"/>
	4	USPTO Office Action dated 07/21/2009 in connection with related Application Serial No. 10/984,683 filed 11/09/2004, Examiner Anna Pagonakis, Art Unit 1614.	<input type="checkbox"/>
	5	Interview Summary dated 10/22/2009 in connection with related Application Serial No. 10/725,965, Examiner Umamaheswari Ramachandran, Art Unit 1627.	<input type="checkbox"/>
	6	KHAN, Arif, MD et al., " Symptom Reduction and Suicide Risk in Patients Treated With Placebo in Antidepressant Clinical Trials -- An Analysis of the Food and Drug Administration Database." Arch Gen Psychiatry, Vol. 57, April 2000, pp.311-317.	<input type="checkbox"/>
	7	MONTGOMERY, Stuart A. et al., "Escitalopram versus venlafaxine XR in the treatment of depression." International Clinical Psychopharmacol, 21:297-309, 2006.	<input type="checkbox"/>
	8	MOORE, Nicholas et al., "Prospective, multicentre, randomized double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder." International Clinical Psychopharmacol, 20:131-137, 2005.	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10580962
	Filing Date	2006-05-31
	First Named Inventor	Erik Buntinx
	Art Unit	1617
	Examiner Name	PIHONAK, Sarah
	Attorney Docket Number	29248-29

9	NELSON, Craig J., et al., "Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials." <i>Am J Psychiatry</i> , September 2009, 166:980-991.	<input type="checkbox"/>
10	PEREMANS, Kathelijne et al., "Evaluation of serotonin-2A receptor occupancy with 123 I-5-I-R91150 and single-photon emission tomography before and after low-dose pipamperone administration in the canine brain." <i>Nuclear Medicine Communications</i> , 29:724-729, 2008. Published and Page Proofs.	<input type="checkbox"/>
11	PRINSSEN, Eric P.M. et al., "The effects of antipsychotics with 5-HT2C receptor affinity in behavioral assays selective for 5-HT2C receptor antagonist properties of compounds." <i>European Journal of Pharmacology</i> , 2000, 388:57-67.	<input type="checkbox"/>
12	Download from www.whocc.no/atcddd/welcome.html dated 08/20/2009, 2 pages.	<input type="checkbox"/>
13	BUNTINX, E. et al., 'Preclinical and clinical evidence for the efficacy of pipamperone in augmenting the antidepressant effects of the SSRI citalopram.' <i>International Journal of Neuropsychopharmacology</i> , volume 1, supplement 1, p. 190, July 2008.	<input type="checkbox"/>
14	BUNTINX E et al., Preclinical and Clinical Evidence for the Efficacy of Pipamperone in Augmenting the Antidepressant Effects of the SSRI Citalopram." Poster presented at the XXVI Collegium Internationale Neuro-Psychopharmacologicum (CINP) Congress 13-17 July 2008, Munich, Germany and Summary Expected Receptor Occupancy (RO) of Pipamperone in vivo.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Sarah Pihonak/	Date Considered	03/30/2010
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.